Latest news with #FionaMarshall
Yahoo
01-05-2025
- Business
- Yahoo
Novartis to acquire Regulus in deal for kidney disease drug
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Novartis will pay $800 million upfront to acquire Regulus Therapeutics, a San Diego biotechnology company that launched nearly two decades ago with plans to make drugs capable of targeting small strips of nucleic acid known as microRNA. Announced Wednesday, the acquisition will hand the Swiss pharmaceutical firm a drug prospect called farabursen, which recently completed a Phase 1b study in people with autosomal dominant polycystic kidney disease, or ADPKD. Per deal terms, Regulus shareholders will receive $7 in cash per share, a premium of more than 100% to the stock's closing price Tuesday. Additionally, Novartis has committed to pay an additional $7 per share via a so-called contingent value right that's linked to the achievement of an unspecified regulatory milestone. Regulus was launched in 2007 as a joint venture between Alnylam Pharmaceuticals and Ionis Pharmaceuticals, building on a paper published in Nature on how a kind of synthetic oligonucleotide could silence microRNA, which plays a role in genetic regulation. After early successes, such as a 2010 partnership with Sanofi and a 2012 deal with AstraZeneca, the biotech hit setbacks from which it struggled to recover. It also had difficulty finding the right application for its drugmaking technology, trying its hand at a hepatitis C treatment that didn't pan out. Since 2021, Regulus shares have traded below $4 per share. The drug at the heart of its deal with Novartis, called farabursen, entered the clinic in 2022. Farabursen targets miR-17, which researchers have identified as potentially relevant to kidney disease. People with ADPKD have few treatment options, relying on the drug tolvaptan to slow the rate of kidney function decline, as well as pain relievers and blood pressure-lowering drugs. Acquiring Regulus is one of several investments Novartis has made in kidney disease, most notably a $3 billion deal in 2023 for Chinook Therapeutics that netted it Venrafia, which won accelerated approval to treat IgA nephropathy earlier this month. It's also developing Fabhalta, already cleared in IgAN, for several other kidney-related conditions. 'This is a meaningful addition to our renal portfolio as we continue driving innovation in kidney care, following our recent approvals of treatments for IgAN and C3G,' Shreeram Aradhye, Novartis' chief medical officer, wrote in a LinkedIn post. The pharma hinted earlier this year that it would continue to be active in dealmaking. Its president of biomedical research, Fiona Marshall, told BioPharma Dive that it was looking for early-stage assets. Novartis previously identified ADPKD as a target in its renal portfolio. 'So often, it's having our own program that makes us really like the project, and then if we see somebody else is doing it better than us externally, we'll still bring that in,' she said in January. Recommended Reading Novartis to acquire kidney disease biotech Chinook for up to $3.5B
Yahoo
24-04-2025
- Business
- Yahoo
Solis Announces Succesful Closing of Tranche 2 Placement
West Leederville, Western Australia--(Newsfile Corp. - April 23, 2025) - The Directors of Solis Minerals Ltd. (ASX: SLM) (TSXV: SLMN) (OTCQB: SLMFF) (FSE: 08W) ("Solis Minerals" or "the Company"), are pleased to advise that the Company has closed Tranche 2 of the Placement, issuing a total of 30,979,957 CHESS Depositary Interests (CDIs) over common shares at A$0.085 per New Share along with 26,470,627 unlisted options exercisable at A$0.16 with a two- year term, to raise gross proceeds of A$2,633,296.35. Assisting brokers received, in aggregate, fees of 6% of the funds raised under the Placement, being a total of $145,697.78 in connection with the closing of Tranche 2. The brokers will also receive 12,632,353 unlisted options exercisable at A$0.14875 with a three-year term. Tranche 2 of the Placement was approved by shareholders at a Special Shareholder Meeting of the Company held 16 April 2025. A further 294,118 CDIs at A$0.085 per New Share along with 147,059 unlisted options exercisable at A$0.16 with a two-year term, are being issued on the same terms for aggregate cash proceeds of A$25,000. The Company's total issued equity capital post Tranche 2 allotment is 141,080,178 shares. Additionally, the Company has issued 6,000,000 performance rights to its CEO and 6,800,000 performance rights to its Directors with the terms and conditions disclosed under Schedules 4 and 5, respectively of the Notice of Special Meeting released to the ASX on 19 March 2025. CDIs trading on the ASX issued on account of the shares cannot be converted into common shares of the Company for the purposes of trading such shares in Canada until four months and one day have elapsed from the issuance date. This announcement is authorised for release by the Board. ContactMitch ThomasChief Executive OfficerSolis Minerals Limited+61 458 890 355 Media & Broker Enquiries:Fiona Marshall & Jason MackWhite Noise Communicationsfiona@ 400 512 109 Neither the TSX Venture Exchange nor its Regulation Service Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this news release. About Solis Minerals Limited Solis Minerals is an emerging exploration company, focused on unlocking the potential of its South American copper portfolio. The Company is building a significant copper portfolio around its core tenements of Ilo Este and Ilo Norte and elsewhere in the Coastal Belt of Peru. Solis holds 81 concessions totalling 69,200 Ha. 47 concessions are granted (39,000 Ha) and 34 concessions are being processed (30,200 Ha). The Company is led by a highly-credentialled and proven team with excellent experience across the mining lifecycle in South America. Solis is actively considering a range of copper opportunities. South America is a key player in the global export market for copper and Solis, under its leadership team, is strategically positioned to capitalise on growth the opportunities within this mineral-rich region. To view the source version of this press release, please visit Sign in to access your portfolio
Yahoo
25-03-2025
- Business
- Yahoo
Solis Minerals Announces TSXV Approval of Tranche 2 Placement Closing Date
Perth, Western Australia--(Newsfile Corp. - March 25, 2025) - Solis Minerals Limited (ASX: SLM) (TSXV: SLMN) (OTCQB: SLMFF) (FSE: 08W) ("Solis Minerals" or "the Company") provides the following update regarding its Tranche 2 placement. Under TSX Venture Exchange ("TSXV") requirements, placements must close within 45 days of announcement. Solis Minerals announced its Tranche 1 and 2 placements on 26 February 2025. To accommodate the Special Shareholder Meeting scheduled for 16 April 2025, the TSXV has granted a 30-day extension from today for the closing of the Tranche 2 placement. This announcement is authorised for release by the Board. ContactMitch ThomasChief Executive OfficerSolis Minerals Limited+61 458 890 355 Media & Broker Enquiries: Fiona Marshall & Jason MackWhite Noise Communications fiona@ 400 512 109 Neither the TSX Venture Exchange nor its Regulation Service Provider (as the term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy of accuracy of this news release. About Solis Minerals Limited Solis Minerals is an emerging exploration company, focused on unlocking the potential of its South American copper portfolio. The Company is building a significant copper portfolio around its core tenements of Ilo Este and Ilo Norte and elsewhere in the Coastal Belt of Peru. Solis holds 81 concessions totalling 69,200 Ha. 47 concessions are fully granted (39,000 Ha) and 34 concessions are being processed (30,200 Ha). The Company is led by a highly-credentialled and proven team with excellent experience across the mining lifecycle in South America. Solis is actively considering a range of copper opportunities. South America is a key player in the global export market for copper and Solis, under its leadership team, is strategically positioned to capitalise on growth the opportunities within this mineral-rich region. To view the source version of this press release, please visit
